Pfizer Inc. (PFE)
Pfizer: Q2 Strength Overshadows Obesity Setbacks
Pfizer shares edged higher after Q2 earnings, shrugging off criticism over the discontinuation of two obesity drug candidates, MET-224o and PF-07976016. PFE highlighted Metsera's rapid progress and plans to strategically deploy its remaining $6 billion-$7 billion toward bolt-on opportunities in oncology, IMIDs, and obesity. In Q2, sales of the tafamidis franchise were $1.76 billion, up 10% QoQ.
Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
PFE raises its 2026 revenue outlook as non-COVID growth, deeper cost cuts and pipeline catalysts offset weaker COVID demand.
Pfizer Q2 Earnings Call Highlights
Pfizer NYSE: PFE reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue increased 1% operationally from a year earlier, while revenue excluding COVID-19 products rose 5% operationally.
PFE Q2 Earnings Top, 2026 Sales View Tweaked, COVID Forecast Cut
Pfizer beats Q2 earnings and revenue estimates, raises the low end of its 2026 sales outlook, but lowers expectations for COVID product revenues.
Compared to Estimates, Pfizer (PFE) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pfizer raises revenue outlook after quarterly earnings top estimates
Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue guidance, as growth from launched and acquired products helped offset declines in its COVID-19 portfolio. The pharmaceutical company reported adjusted earnings of $0.77 per share for the quarter, above the $0.68 expected by analysts.
Pfizer (PFE) Q2 Earnings and Revenues Top Estimates
Pfizer (PFE) came out with quarterly earnings of $0.77 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago.
Pfizer Post Loss on Higher Revenue
Pfizer swung to a second-quarter loss but posted higher revenue, as market growth in its oncology business offset some declines in its Covid-19 products.
Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
Pfizer reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, citing the stronger-than-expected performance of non-Covid products. The company is now expecting full-year revenue to total $60.5 billion to $62.5 billion, which compares to a previous outlook of $59.5 billion to $62.5 billion.
Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings
Pfizer beats earnings forecasts for the second quarter, while BioNTech's results miss expectations due to weak Covid vaccine demand.
Pfizer's Bear Case Is Breaking
Pfizer's non-COVID commercial portfolio is accelerating, with new launches and business development products growing 22% to a nearly $12 billion annualized run rate. Seagen's oncology portfolio expanded 20% while Biohaven's migraine franchise surged 41%, demonstrating strong commercial momentum beyond the COVID business. COVID revenue is expected to decline from $11 billion in 2024 to approximately $5 billion in 2026, increasing reliance on newer growth drivers.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
